Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience.
Anti-thyroid drugs
Hyperthyroidism
Outcome
Radioactive iodine therapy
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
17
09
2020
accepted:
24
11
2020
pubmed:
6
1
2021
medline:
9
7
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Aim of our study was to search for variables associated with worse outcomes in patients treated with radioactive iodine (RAI) for hyperthyroidism by a dosimetric-based approach. Four hundred twenty-four patients with hyperthyroidism related to Toxic Multinodular Goiter (TMG; n = 213), Grave's disease (GD; n = 150) and toxic adenoma (TA; n = 61) treated with RAI between 2000 and 2018 and with at least 12 months follow-up were retrospectively evaluated. Association between outcomes (response vs. no response) at 6 and 12 months and baseline TSH values, anti-thyroid drugs (ATD) duration and posology, RAI absorbed dose and dimensional reduction of target mass at ultrasound was evaluated by Mann-Whitney test. Risk factors for response vs. no-response were analysed by binary logistic regression model. Overall response rate was 78.7 and 83% at 6 and 12 months, respectively. Both at 6 and 12 months higher TSH baseline values (p < 0.001), lower ATD duration (p = 0.004 and p = 0.043), lower ATD posology (p = 0.014 and p = 0.005), and lower dose to target (D Low TSH levels, longer duration and higher posology of ATD were associated with worse response to RAI. These data confirm that RAI therapy should be considered earlier in patients' management to allow better outcome and avoid ATD toxicity.
Identifiants
pubmed: 33400175
doi: 10.1007/s12020-020-02573-1
pii: 10.1007/s12020-020-02573-1
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-115Références
D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10), 1343–421 (2016)
doi: 10.1089/thy.2016.0229
G.J. Kahaly, L. Bartalena, L. Hegedüs, L. Leenhardt, K. Poppe, S.H. Pearce, 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Eur. Thyroid J. 7(4), 167–86 (2018)
doi: 10.1159/000490384
S. De Leo, S.Y. Lee, L.E. Braverman, Hyperthyroidism. Lancet 388(10047), 906–18 (2016)
doi: 10.1016/S0140-6736(16)00278-6
P. Vejbjerg, N. Knudsen, H. Perrild et al. Lower prevalence of mild hyperthyroidism related to a higher iodine intake in the population: prospective study of a mandatory iodization programme. Clin. Endocrinol. 71, 440–5 (2009)
doi: 10.1111/j.1365-2265.2008.03493.x
National Institute for Health and Care Excellence. Thyroid disease: assessment and management (NICE, London, 2019). https://www.nice.org.uk/guidance/ng145
D.S. Cooper, Antithyroid drugs. N. Engl. J. Med. 352, 905–17 (2005)
doi: 10.1056/NEJMra042972
M.P.M. Stokkel, D. Handkiewicz Junak, M. Lassmann, M. Dietlein, M. Luster, EANM procedure guidelines for therapy of benign thyroid disease. Eur. J. Nucl. Med Mol. Imaging 37(11), 2218–28 (2010)
doi: 10.1007/s00259-010-1536-8
A. De Rooij, J. Vandenbroucke, J. Smit, M. Stokkel, O. Dekkers, Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur. J. Endocrinol. 161(5), 771–7 (2009)
doi: 10.1530/EJE-09-0286
S. Bonnema, H. Bertelsen, J. Mortensen, P. Andersen, D. Knudsen, L. Bastholt et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J. Clin. Endocrinol. Metab. 84, 3636–41 (1999)
pubmed: 10523007
B. Nygaard, L. Hegedus, P. Ulriksen, K. Nielsen, J. Hansen, Radioiodine therapy for multinodular toxic goiter. Arch. Intern. Med. 159, 1364–8 (1999)
doi: 10.1001/archinte.159.12.1364
L. Bartalena, L. Baldeschi, K. Boboridis, A. Eckstein, G.J. Kahaly, C. Marcocci et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur. Thyroid J. 5(1), 9–26 (2016)
doi: 10.1159/000443828
M. McDermott, G. Kidd, L.J. Dodson, F. Hofeldt, Radioiodine-induced thyroid storm. Case report and literature review. Am. J. Med. 75, 353–9 (1983)
doi: 10.1016/0002-9343(83)91217-2
M.A. Walter, M. Briel, M. Christ-Crain, S.J. Bonnema, J. Connell, D.S. Cooper et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334(7592), 514 (2007)
doi: 10.1136/bmj.39114.670150.BE
W. Snyder, M. Ford, G. Warner, S. Watson, “S,” absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pam No 11, (Soc Nucl Med New York, NY, 1975)
M.T. Sapienza, G.B. Coura-Filho, J. Willegaignon, T. Watanabe, P.S. Duarte, C.A. Buchpiguel, Clinical and dosimetric variables related to outcome after treatment of graves’ disease with 550 and 1110 MBq of 131I: Results of a prospective randomized trial. Clin. Nucl. Med. 40(9), 715–9 (2015)
doi: 10.1097/RLU.0000000000000840
R. Santos, J. Romaldini, L. Ward, A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. Clin. Nucl. Med. 37, 241–4 (2012)
doi: 10.1097/RLU.0b013e31823ea6e0
L. Vija Racaru, C. Fontan, M. Bauriaud-Mallet, S. Brillouet, O. Caselles, S. Zerdoud et al. Clinical outcomes 1 year after empiric131I therapy for hyperthyroid disorders: Real life experience and predictive factors of functional response. Nucl. Med Commun. 38(9), 756–63 (2017)
doi: 10.1097/MNM.0000000000000705
C. Reiners, P. Schneider, Radioiodine therapy of thyroid autonomy. Eur. J. Nucl. Med. 29(Suppl 2), S471–8 (2002)
doi: 10.1007/s00259-002-0910-6
C. Ceccarelli, W. Bencivelli, P. Vitti, L. Grasso, A. Pinchera, Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin. Endocrinol. 62, 331–5 (2005)
doi: 10.1111/j.1365-2265.2005.02218.x
E. Amato, A. Campennì, S. Leotta, R. Ruggeri, S. Baldari, Treatment of hyperthyroidism with radioiodine targeted activity: a comparison between two dosimetric methods. Phys. Med. 32(6), 847–53 (2016)
doi: 10.1016/j.ejmp.2016.05.059
L. Giovanella, ed. Nuclear medicine therapy, side effects and complications (Springer, Cham, 2019)
M.A. Walter, M. Christ-Crain, C. Schindler, J. Müller-Brand, B. Müller, Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur. J. Nucl. Med. Mol. Imaging 33(6), 730–7 (2006)
doi: 10.1007/s00259-006-0092-8
L.D. Hancock, R.M. Tuttle, H. LeMar, J. Bauman, T. Patience, The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves’ disease. Clin. Endocrinol. 47(4), 425–30 (1997)
doi: 10.1046/j.1365-2265.1997.2741075.x
R.E. Imseis, L. Vanmiddlesworth, J.D. Massie, A.J. Bush, N.R. Vanmiddlesworth, Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J. Clin. Endocrinol. Metab. 83(2), 685–7 (1998)
doi: 10.1210/jcem.83.2.4538
R.M. Tuttle, T. Patient, S. Buss, Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves’ disease. Thyroid 5(4), 243–7 (1995)
doi: 10.1089/thy.1995.5.243
R.B. Santos, J.H. Romaldini, L.S. Ward, Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid 14(7), 525–30 (2004)
doi: 10.1089/1050725041517093
A. Lewis, T. Rea, B. Atkinson, P. Bell, H. Courtney, D. Mccance et al. Outcome of 131 I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulst. Med J. 82(2), 85–8 (2013)
E. Aung, N. Zammitt, A. Dover, M. Strachan, J. Seckl, F. Gibb, Predicting outcomes and complications following radioiodine therapy in Graves’ thyrotoxicosis. Clin. Endocrinol. 90, 192–9 (2019)
doi: 10.1111/cen.13873
M. Finessi, V. Liberini, D. Deandreis, Dosimetrically determined activities in advanced differentiated thyroid carcinoma–controversies. Q. J. Nucl. Med Mol. imaging 63(3), 258–66 (2019)
doi: 10.23736/S1824-4785.19.03211-4